Esperion Therapeutics Inc. (ESPR)
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year.
Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Betty Jean Swartz - Chief Business Officer Conference Call Participants Dennis Ding - Jefferies Joseph Pantginis - H.C. Wainwright Jason Zemansky - Bank of America Kristen Kluska - Cantor Fitzgerald Jessica Fye - J.P.
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.34 per share a year ago.
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Esperion Therapeutics (ESPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates.
Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Eric Warren - Chief Commercial Officer Conference Call Participants Dennis Ding - Jefferies Joseph Pantginis - H.C. Wainwright Thomas Shrader - BTIG Tanmay Patwardhan - JPMorgan Jason Zemansky - Bank of America Serge Belanger - Needham Paul Choi - Goldman Sachs Kristen Kluska - Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by, and welcome.
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.50 per share a year ago.
Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will The Long Awaited Breakout For Esperion Therapeutics Hold?
Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical achievements and strategic moves, including global drug submissions, bolster the stock's outlook. The Piper Sandler Conference reinforced Esperion's growth strategy, with CEO Sheldon Koenigand CFO Ben Halladay providing encouraging news on guidance and business performance.
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and cardiovascular risk. Shares rise.
